FDA Prepares To Update Drug-Induced Liver Injury Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
A March stakeholder conference is set to consider questions unresolved by the agency's two-year-old guidelines.
You may also be interested in...
FDA Liver Injury Conference Another Chance To Inform Guidance Changes
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials
Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.
Where A REMS Didn't Help: Sanofi Must Deal With Liver Injuries With Multaq
Company has sent a "Dear Dr." letter describing rare cases of liver problems and will also send additional data to FDA from the clinical trials.